A Targeted Electronic Health Approach to Reduce Fear of Recurrence in Breast Cancer Survivors (FoRtitude)

Not Applicable

Not yet recruiting

• Conditions: Breast Cancer Survivor; Fear of Cancer Recurrence

• Registration Number: NCT07122492
• Lead Sponsor: Eastern Cooperative Oncology Group

Brief Summary

The goal of this study is to determine if the intervention or if general information about being a breast cancer survivor can help Breast Cancer Survivors reduce their fear of recurrence. The main question it aims to answer are:

Can the FoRtitude intervention lower the fear of recurrence for Breast Cancer Survivors?

Participants will:

Answer questions about their fear of recurrence. Be randomized to 1 of the 3 following options: (1) a weblink to access an eHealth intervention which includes a website and an optional interactive text-messaging feature, (2) a weblink to a non-interactive website that will include links to external websites with general information that may be helpful for Breast Cancer Survivors, or (3) you will need to talk with your oncology team about your concerns about recurrence or seek psychosocial care in the community.

Be asked to fill out questionnaires 5 times for up to 18 months.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-08
• Study First Submitted: 2025-08-07
• Study First Submitted QC: 2025-08-07
• Last Update Submitted: 2025-08-07
• Study First Posted: 2025-08-14
• Last Update Posted: 2025-08-14
• Study Start: 2025-09-01
• Primary Completion: 2028-09-01
• Study Completion: 2029-09-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Female
• Target Recruitment: 800

Inclusion Criteria

• Participant must be ≥ 18 years of age.
• Participant must have had histologically confirmed Stage 0-III breast cancer at time of diagnosis.
• Participant must have completed primary treatment 1-10 years prior to Step 0 registration.

NOTE: Current hormonal therapy is allowed. NOTE: Primary treatment can include chemotherapy and/or surgery and/or radiation therapy.

• Participant must be receiving their care (cancer treatment or survivorship care) from an oncology provider affiliated with the NCORP site and are expected to continue care at the site for the next 18 months.

NOTE: This eligibility criteria is intended to ensure access to healthcare utilization data. Oncology provider can include an Advance Practice Provider, Advance Nurse Practitioner, oncologist, primary care provider, or nurse or physician responsible for survivorship care.

• Participant must have no evidence of active cancer of any type at the time of Step 0 registration (per the assessment of the physician), excluding local basal cell or squamous cell carcinoma.
• Participant must be fluent in written and spoken English.
• Participant must have an ECOG Performance Status of 0-2.
• Participant must have the ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) are not eligible.
• Participant must complete the FCRI 9-item severity scale and report a score of 13 or higher.
• Participant must have access to the internet (via smartphone, tablet, or computer).

NOTE: The restriction to those with internet access is based on the primary intention of the study which involves internet-based delivery intervention content delivered via the internet.

• Participant must have completed the Baseline Assessment within 60 days of Step 0 registration.
• Randomization to Step 1 must occur within 60 days of Step 0 registration.

Exclusion Criteria

• Participant must not have any psychiatric or cognitive conditions that may affect the participant's ability to accurately provide self-report data, per clinical discretion.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Fear of Cancer Recurrence Inventory (FCRI)	From 1 month post-intervention to 3 months post-intervention	Fear of Cancer Recurrence Inventory (FCRI) modified total score 143 (without coping or reassurance subscale items) measured during the study period. A graphical exploration of the data will be performed by examining the distribution of FCRI score at each follow up timepoint, as well as the changes in FCRI between the baseline and follow up visits. 1-month post-intervention completion (3 months post-randomization) will be defined as the primary comparison. For the primary analysis we will compare the FCRI score of the FoRtitude arm to each of two control arms at 3 months using Welch's t-test. Two two-group Welch's t-tests will be used to compare the FCRI score of the FoRtitude arm to each of the two control arms at 12 weeks.

Secondary Outcome Measures

Name	Time	Method
Difference in fear of recurrence based on race across all arms	From enrollment to 3 months	A mixed model, including indicator variables for arm, race, and time, will be used and will include the interactions of race by arm and race by time. The FCRI modified total score of the FoRtitude arm to each of two control arms will be compared at 3 months using a two-group t-test with linear contrasts.
Change in quality of life measures	At all time points, including long term outcomes at 6, 12 and 18 months.	A per-comparison-wise error rate approach (PCWER) will be used.

Trial Locations

Locations (1)

UNC Chapel Hill School of Medicine Public Health; 🇺🇸 Chapel Hill, North Carolina, United States